National report - The benefits of Allergan's proposed oral psoriasis drug, Tazoral, do not outweigh possible risks of birth defects and bone loss, a U.S. Food and Drug Administration advisory panel has decided.
Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence
The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition
POLL: What Strategies Have You Found Most Effective in Managing Alopecia?
The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice
Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging
Pointers With Portela: What to Know About Ozempic